Targeted BIRC5 silencing using YM155 causes cell death in neuroblastoma cells with low ABCB1 expression

European Journal of Cancer

Volumn 48, Issue 5, 2012, Pages 763-771

  Lamers, Fieke ^a   Schild, Linda ^a   Koster, Jan ^a   Versteeg, Rogier ^a   Caron, Huib N ^a   Molenaar, Jan J ^a  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

Author keywords

ABCB1; Apoptosis; BIRC5; Cancer; Neuroblastoma; YM155

Indexed keywords

CYCLOSPORIN; LENTIVIRUS VECTOR; MESSENGER RNA; MULTIDRUG RESISTANCE PROTEIN 1; SEPANTRONIUM BROMIDE; SHORT HAIRPIN RNA; SURVIVIN;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER RESISTANCE; CHILD; CONTROLLED STUDY; DRUG EFFICACY; DRUG SENSITIVITY; GENE EXPRESSION; GENE SILENCING; GENE TARGETING; HUMAN; HUMAN CELL; IC 50; NEUROBLASTOMA CELL; PRIORITY JOURNAL; TUMOR CELL; TUMOR INITIATING CELL; WESTERN BLOTTING;

APOPTOSIS; CELL LINE, TUMOR; DRUG RESISTANCE, NEOPLASM; GENE SILENCING; HEK293 CELLS; HUMANS; IMIDAZOLES; INHIBITOR OF APOPTOSIS PROTEINS; NAPHTHOQUINONES; NEUROBLASTOMA; P-GLYCOPROTEIN; RNA, SMALL INTERFERING; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84858707750     PISSN: 09598049     EISSN: 18790852     Source Type: Journal    
DOI: 10.1016/j.ejca.2011.10.012     Document Type: Article

References (34)

1. J.R. Fangusaro, H. Caldas, Y.Y. Jiang, and R.A. Altura Survivin: an inhibitor of apoptosis in pediatric cancer Pediatr Blood Cancer 47 2006 4 13 (Pubitemid 43787902)
2. Z.Y. Song, X.B. Yao, and M. Wu Direct interaction between survivin and Smac/DIABLO is essential for the anti-apoptotic activity of survivin during taxol-induced apoptosis J Biol Chem 278 2003 23130 23140 (Pubitemid 36830379)
3. S.P. Wheatley, and A. McNeish Survivin: A protein with dual roles in mitosis and apoptosis Int Rev Cytol Surv Cell Biol 247 2005 35
4. M. Castedo, J.L. Perfettini, and T. Roumie Cell death by mitotic catastrophe: a molecular definition Oncogene 23 2004 2825 2837 (Pubitemid 38638845)
5. M. Castedo, J.L. Perfettini, and T. Roumier Mitotic catastrophe constitutes a special case of apoptosis whose suppression entails aneuploidy Oncogene 23 2004 4362 4370 (Pubitemid 38850415)
6. D.C. Altieri The case for survivin as a regulator of microtubule dynamics and cell-death decisions Curr Opin Cell Biol 18 2006 609 615 (Pubitemid 44692469)
7. S.M.A. Lens, R.M.F. Wolthuis, and R. Klompmaker Survivin is required for a sustained spindle checkpoint arrest in response to lack of tension EMBO J 22 2003 2934 2947 (Pubitemid 36758615)
8. G.M. Brodeur Neuroblastoma: biological insights into a clinical enigma Nat Rev Cancer 3 2003 203 216 (Pubitemid 37328872)
9. J.M. Maris, M.D. Hogarty, R. Bagatell, and S.L. Cohn Neuroblastoma Lancet 369 2007 2106 2120 (Pubitemid 46935947)
10. J.M. Maris Medical progress: recent advances in neuroblastoma N Engl J Med 362 2010 2202 2211
11. F. Lamers, I. van der Ploeg, and L. Schild Knockdown of survivin (BIRC5) causes apoptosis in neuroblastoma via mitotic catastrophe Endocr Relat Cancer 18 2011 657 668
12. S.W. Fesik Promoting apoptosis as a strategy for cancer drug discovery Nat Rev Cancer 5 2005 876 885 (Pubitemid 41746032)
13. J.C. Reed, and M. Pellecchia Apoptosis-based therapies for hematologic malignancies Blood 106 2005 408 418 (Pubitemid 40981231)
14. J.J. Molenaar, M.E. Ebus, and D. Geerts Inactivation of CDK2 is synthetically lethal to MYCN over-expressing cancer cells Proc Natl Acad Sci USA 106 2009 12968 12973
15. T. Van Maerken, L. Ferdinande, and J. Taildeman Antitumor activity of the selective MDM2 antagonist Nutlin-3 against chemoresistant neuroblastoma with wild-type p53 J Natl Cancer Inst 101 2009 1562 1574
16. M.M. van Noesel, and R. Versteeg Pediatric neuroblastomas: genetic and epigenetic 'Danse Macabre' Gene 325 2004 1 15 (Pubitemid 38030371)
17. K.C. Goldsmith, B.J. Lestini, and M. Gross BH3 response profiles from neuroblastoma mitochondria predict activity of small molecule Bcl-2 family antagonists Cell Death Differ 17 2010 872 882
18. B.J. Lestini, K.C. Goldsmith, and M.N. Fluchel Mcl1 downregulation sensitizes neuroblastoma to cytotoxic chemotherapy and small molecule Bcl2-family antagonists Cancer Biol Ther 8 2009 1587 1595
19. P. Sapra, M. Wang, R. Bandaru, H. Zhao, L.M. Greenberger, and I.D. Horak Down-modulation of survivin expression and inhibition of tumor growth in vivo by EZN-3042, a locked nucleic acid antisense oligonucleotide Nucleosides Nucleotides Nucleic Acids 29 2010 97 112
20. B.M. Ryan, N. O'Donovan, and M.J. Duffy Survivin: a new target for anti-cancer therapy Cancer Treat Rev 35 2009 553 562
21. T. Nakahara, M. Takeuchi, and I. Kinoyama YM155, a novel small-molecule survivin suppressant, induces regression of established human hormone-refractory prostate tumor xenografts Cancer Res 67 2007 8014 8021 (Pubitemid 47395135)
22. T. Satoh, I. Okamoto, and M. Miyazaki Phase I study of YM155, a novel survivin suppressant, in patients with advanced solid tumors Clin Cancer Res 15 2009 3872 3880
23. A.W. Tolcher, A. Mita, and L.D. Lewis Phase I and pharmacokinetic study of YM155, a small-molecule inhibitor of survivin J Clin Oncol 26 2008 5198 5203
24. K.D. Lewis, W. Samlowski, and J. Ward A multi-center phase II evaluation of the small molecule survivin suppressor YM155 in patients with unresectable stage III or IV melanoma Invest New Drugs 29 2011 161 166
25. G. Giaccone, P. Zatloukal, and J. Roubec Multicenter phase II trial of YM155, a small-molecule suppressor of survivin, in patients with advanced, refractory, non-small-cell lung cancer J Clin Oncol 27 2009 4481 4486
26. R. Evers, M. Kool, and A.J. Smith Inhibitory effect of the reversal agents V-104, GF120918 and pluronic L61 on MDR1 Pgp-, MRP1- and MRP2-mediated transport Br J Cancer 83 2000 366 374 (Pubitemid 30453578)
27. F. Shen, S. Chu, and A.K. Bence Quantitation of doxorubicin uptake, efflux, and modulation of multidrug resistance (MDR) in MDR human cancer cells J Pharmacol Exp Ther 324 2008 95 102 (Pubitemid 350294163)
28. A.J. Smith, U. Mayer, A.H. Schinkel, and P. Borst Availability of PSC833, a substrate and inhibitor of P-glycoproteins, in various concentrations of serum J Natl Cancer Inst 90 1998 1161 1166 (Pubitemid 28380721)
29. J.J. Molenaar, M.E. Ebus, and J. Koster Cyclin D1 and CDK4 activity contribute to the undifferentiated phenotype in neuroblastoma Cancer Res 68 2008 2599 2609 (Pubitemid 351556258)
30. O. Morozova, M. Vojvodic, and N. Grinshtein System-level analysis of neuroblastoma tumor-initiating cells implicates AURKB as a novel drug target for neuroblastoma Clin Cancer Res 16 2010 4572 4582
31. H. Glavinas, P. Krajcsi, J. Cserepes, and B. Sarkadi The role of ABC transporters in drug resistance, metabolism and toxicity Curr Drug Deliv 1 2004 27 42
32. P. Imming, C. Sinning, and A. Meyer Drugs, their targets and the nature and number of drug targets (vol 5, pg 821, 2006) Nat Rev Drug Discov 6 2007 126
33. L. Zhang, K.M. Smith, and A.L. Chong In vivo antitumor and antimetastatic activity of sunitinib in preclinical neuroblastoma mouse model Neoplasia 11 2009 426 435
34. S. Nobili, I. Landini, B. Giglioni, and E. Mini Pharmacological strategies for overcoming multidrug resistance Curr Drug Targets 7 2006 861 879